PRAMEF25 Inhibitors
PRAMEF25 inhibitors are a class of chemical compounds designed to specifically target and inhibit the function of PRAMEF25, which stands for Preferentially Expressed Antigen in Melanoma Family Member 25. PRAMEF25 belongs to the PRAME (Preferentially Expressed Antigen in Melanoma) gene family, a group of genes known for their role in modulating transcriptional regulation and cellular growth. Although the precise biological functions of PRAMEF25 remain less characterized compared to other members of the PRAME family, it is believed to play a role in gene expression regulation, potentially influencing cellular processes such as differentiation, proliferation, and apoptosis. PRAME family proteins typically interact with transcriptional repressors or co-activators, suggesting that PRAMEF25 might similarly participate in modulating gene expression by interacting with various transcriptional complexes. Inhibition of PRAMEF25 provides researchers with a tool to explore its specific contributions to these regulatory processes.
In research, PRAMEF25 inhibitors are valuable for investigating the molecular mechanisms by which PRAMEF25 influences gene regulation and its broader impact on cellular functions. By blocking PRAMEF25 activity, scientists can examine how its inhibition alters transcriptional networks, focusing on the downstream effects on gene expression and cellular behavior. This inhibition allows researchers to study how PRAMEF25 may be involved in controlling cellular differentiation and the maintenance of cellular identity, particularly in developmental contexts or during changes in the cellular environment. Additionally, PRAMEF25 inhibitors can help explore interactions between PRAMEF25 and other members of the PRAME family or transcriptional regulators, providing insight into the complex signaling pathways and regulatory networks that govern cellular growth and function. Through these studies, the use of PRAMEF25 inhibitors enhances our understanding of transcriptional regulation, the role of PRAME family proteins in gene expression, and the broader implications of PRAMEF25 activity in maintaining cellular homeostasis.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine could potentially cause demethylation of the PRAMEF25 gene promoter, leading to a decrease in transcriptional activity of the gene. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Suberoylanilide Hydroxamic Acid may downregulate PRAMEF25 by altering the acetylation state of histones associated with its gene, resulting in tighter chromatin and less transcription. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $214.00 $316.00 $418.00 | 7 | |
5-Aza-2′-Deoxycytidine could lead to a reduction in PRAMEF25 expression by decreasing DNA methylation levels, which may silence the gene's transcription. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A has the potential to suppress the transcription of PRAMEF25 by inhibiting histone deacetylase, thereby increasing histone acetylation and altering gene expression. | ||||||
Disulfiram | 97-77-8 | sc-205654 sc-205654A | 50 g 100 g | $52.00 $87.00 | 7 | |
Disulfiram may reduce PRAMEF25 levels by disrupting cellular pathways that control the transcription factors governing the expression of this gene. | ||||||
Belinostat | 414864-00-9 | sc-269851 sc-269851A | 10 mg 100 mg | $153.00 $561.00 | ||
Belinostat could lead to the suppression of PRAMEF25 through inhibition of histone deacetylases, which might result in condensed chromatin structure at the gene locus. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $128.00 $505.00 | 2 | |
RG 108 might inhibit the initiation of PRAMEF25 gene transcription by blocking the methylation of cytosine-phosphate-guanine (CpG) islands within its promoter region. | ||||||
Zebularine | 3690-10-6 | sc-203315 sc-203315A sc-203315B | 10 mg 25 mg 100 mg | $126.00 $278.00 $984.00 | 3 | |
Zebularine may decrease PRAMEF25 expression by acting as a cytidine analog, thereby inhibiting DNA methyltransferase and subsequent gene silencing. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein could downregulate the expression of PRAMEF25 by inhibiting specific tyrosine kinases that activate transcriptional pathways for this gene. | ||||||
Parthenolide | 20554-84-1 | sc-3523 sc-3523A | 50 mg 250 mg | $79.00 $300.00 | 32 | |
Parthenolide may indirectly inhibit the expression of PRAMEF25 by interfering with the NF-κB pathway, which could be responsible for the upregulation of this gene. | ||||||